MLM Share Price

Open 0.46 Change Price %
High 0.46 1 Day 0.00 0.00
Low 0.45 1 Week 0.01 2.22
Close 0.46 1 Month 0.03 6.98
Volume 1605301 1 Year 0.10 27.78
52 Week High 0.64
52 Week Low 0.29
MLM Important Levels
Resistance 2 0.47
Resistance 1 0.47
Pivot 0.46
Support 1 0.45
Support 2 0.45
BIT Italy Most Active Stocks
ISP 2.54 -0.39%
TIT 0.84 0.00%
PMI 0.36 0.00%
PMI 0.36 0.00%
SPM 0.40 0.00%
SPM 0.40 0.00%
F 6.94 -2.12%
F 6.94 -2.12%
F 6.94 -2.12%
F 6.94 -2.12%
More..
BIT Italy Top Gainers Stocks
STEF 0.17 30.77%
BCM 0.18 20.00%
BCM 0.18 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
ROS 1.34 13.56%
ROS 1.34 13.56%
TER 1.04 11.83%
More..
BIT Italy Top Losers Stocks
MEC 0.16 -5.88%
MEC 0.16 -5.88%
MEC 0.16 -5.88%
POL 0.17 -5.56%
POL 0.17 -5.56%
POL 0.17 -5.56%
POL 0.17 -5.56%
CIA 0.20 -4.76%
CIA 0.20 -4.76%
CIA 0.20 -4.76%
More..

Molmed (BIT: MLM)

MLM Technical Analysis 4
As on 24th Mar 2017 MLM Share Price closed @ 0.46 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.40 & Strong Buy for SHORT-TERM with Stoploss of 0.43 we also expect STOCK to react on Following IMPORTANT LEVELS.
MLM Target for March
1st Target up-side 0.45
2nd Target up-side 0.48
3rd Target up-side 0.5
1st Target down-side 0.39
2nd Target down-side 0.36
3rd Target down-side 0.34
MLM Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.molmed.com
MLM Address
MLM
Via Olgettina, 58
Milan, MI 20132
Italy
Phone: 39 02 212771
Fax: 39 02 21 27 73 25
MLM Latest News
Southwest Floridians letting food be their medicine   The News-Press   - 24th Feb 17
Vie Collection Launches WRINKLE DIMENSION Hyaluronic Acid Concetrate   PR Web (press release)   - 29th Jan 17
Future Predictions for 2017-2045   Anti Aging News   - 06th Jan 17
Berlusconi Campaigns for 'No' as His Top Managers Back Renzi   Bloomberg   - 23rd Nov 16
The Mast Cell: New Target in SpA?   MedPage Today   - 12th Nov 16
A Pedicure Will Not Cure Postpartum Depression   American Council on Science and Health   - 04th Nov 16
Correction for Aamot et al., Genotyping of 353 Staphylococcus aureus ...   Journal of Clinical Microbiology   - 24th Aug 16
BABOR Announces Partnership with Renowned Mario Tricoci Hair Salons and Day Spas   PR Web (press release)   - 08th Aug 16
, a Breakthrough in Viscoelastic Technology, at the American Orthopaedic ...   Business Wire (press release)   - 06th Jul 16
DiaSorin SpA Completes Acquisition of the Focus Diagnostics' Molecular and ...   PR Newswire (press release)   - 14th May 16
Interactive Technical Analysis Chart Molmed ( MLM BIT Italy )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Molmed
MLM Business Profile
MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of therapies to treat cancer. Its products include TK, a cell therapy product, which is in Phase III clinical trials enabling safe transplant of haematopoietic stem cells from partially compatible haplo-identical donors for the treatment of haematological malignancies. The company’s products also comprise NGR-hTNF, a recombinant biological drug that is in Phase II clinical trials for various types of solid tumours, such as colorectal, hepatocellular carcinoma and mesothelioma, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, and soft-tissue sarcoma, as well as is in Phase III clinical trials in mesothelioma patients. It has an agreement with Telethon Foundation for the co-development and clinical-grade manufacture of gene therapies for rare genetic diseases; San Raffaele Foundation for the clinical-grade manufacturing of a cell therapy for Duchenne muscular dystrophy; and GlaxoSmithKline for the development and production for clinical use of a viral vector for ADA, as well as a strategic partnership with Takara Bio, Inc. for TK cell therapy. The company was founded in 1996 and is based in Milan, Italy.